The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy

Immunological Reviews

Volumn 220, Issue 1, 2007, Pages 47-59

  Apetoh, Lionel ^a,b,c   Ghiringhelli, François ^a,b,c,d   Tesniere, Antoine ^a,b,c   Criollo, Alfredo ^a,b,c   Ortiz, Carla ^a,b,c   Lidereau, Rosette ^e   Mariette, Christophe ^f   Chaput, Nathalie ^a,c,d   Mira, Jean Paul ^g   Delaloge, Suzette ^a   André, Fabrice ^a   Tursz, Thomas ^a,b,c   Kroemer, Guido ^a,b,c   Zitvogel, Laurence ^a,b,c,d  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSERM   (France)

^d IGR   (France)

^e CENTRE RENÉ HUGUENIN   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g INSTITUT COCHIN   (France)

Author keywords

Anti tumor vaccination; Chemotherapy; Dendritic cell; HMGB1; TLR4

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BAFILOMYCIN A1; CHLOROQUINE; DOCETAXEL; DOXORUBICIN; HIGH MOBILITY GROUP B1 PROTEIN; IRINOTECAN; OXALIPLATIN; TOLL LIKE RECEPTOR 4;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER THERAPY; CELL DEATH; DENDRITIC CELL; DNA POLYMORPHISM; HORMONAL THERAPY; HUMAN; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN SECRETION; RELAPSE; REVIEW; TUMOR CELL; TUMOR REGRESSION;

EID: 35748942876     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2007.00573.x     Document Type: Review

References (80)

1. Chabner BA, Roberts TG Jr. Timeline: chemotherapy and the war on cancer. Nat Rev Cancer 2005 5 : 65 72.
2. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with toll-like receptor agonists and antagonists. Nat Med 2007 13 : 552 559.
3. Phan GQ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003 100 : 8372 8377.
4. Hirano F, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005 65 : 1089 1096.
5. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005 5 : 296 306.
6. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998 392 : 245 252.
7. Janeway CA Jr. How the immune system works to protect the host from infection: a personal view. Proc Natl Acad Sci USA 2001 98 : 7461 7468.
8. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila toll protein signals activation of adaptive immunity. Nature 1997 388 : 394 397.
9. Medzhitov R, Janeway CA Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell 1997 91 : 295 298.
10. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994 12 : 991 1045.
11. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999 5 : 1249 1255.
12. Kurts C, Miller JF, Subramaniam RM, Carbone FR, Heath WR. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J Exp Med 1998 188 : 409 414.
13. Shi Y, Rock KL. Cell death releases endogenous adjuvants that selectively enhance immune surveillance of particulate antigens. Eur J Immunol 2002 32 : 155 162.
14. Tabeta K, et al. The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9. Nat Immunol 2006 7 : 156 164.
15. Janssen E, et al. Efficient T cell activation via a toll-interleukin 1 receptor-independent pathway. Immunity 2006 24 : 787 799.
16. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003 425 : 516 521.
17. la Sala A, Ferrari D, Corinti S, Cavani A, Di Virgilio F, Girolomoni G. Extracellular ATP induces a distorted maturation of dendritic cells and inhibits their capacity to initiate Th1 responses. J Immunol 2001 166 : 1611 1617.
18. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006 6 : 823 835.
19. Jiang D, et al. Regulation of lung injury and repair by toll-like receptors and hyaluronan. Nat Med 2005 11 : 1173 1179.
20. Zubrod CG. The national program for cancer chemotherapy. JAMA 1972 222 : 1161 1162.
21. Johnson J, Monks A, Hollingshead M, Sausville E In : Chabner BA, Longo D, eds. Cancer Chemotherapy and Biotherapy. Philadelphia : Lippincott Williams & Wilkins, 2001 : 17 36.
22. Takimoto CH. Anticancer drug development at the US National Cancer Institute. Cancer Chemother Pharmacol 2003 52 (Suppl.) : S29 S33.
23. Kelland LR. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer 2004 40 : 827 836.
24. Casares N, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005 202 : 1691 1701.
25. Apetoh L, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007 13 : 1050 1059.
26. Granda TG, et al. Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma. Br J Cancer 2002 86 : 999 1005.
27. Bauer AK, et al. Toll-like receptor 4 in butylated hydroxytoluene-induced mouse pulmonary inflammation and tumorigenesis. J Natl Cancer Inst 2005 97 : 1778 1781.
28. Beutler B, et al. Genetic analysis of host resistance: toll-like receptor signaling and immunity at large. Annu Rev Immunol 2006 24 : 353 389.
29. Jung S, et al. In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell-associated antigens. Immunity 2002 17 : 211 220.
30. Biragyn A, et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 2002 298 : 1025 1029.
31. Park JS, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006 290 : C917 C924.
32. Tsung A, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 2005 201 : 1135 1143.
33. Yang D, Chen Q, Yang H, Tracey KJ, Bustin M, Oppenheim JJ. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol 2007 81 : 59 66.
34. Bianchi ME, Beltrame M, Paonessa G. Specific recognition of cruciform DNA by nuclear protein HMG1. Science 1989 243 : 1056 1059.
35. Einck L, Bustin M. The intracellular distribution and function of the high mobility group chromosomal proteins. Exp Cell Res 1985 156 : 295 310.
36. Andersson U, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000 192 : 565 570.
37. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002 418 : 191 195.
38. Park JS, et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004 279 : 7370 7377.
39. Dumitriu IE, Baruah P, Bianchi ME, Manfredi AA, Rovere-Querini P. Requirement of HMGB1 and RAGE for the maturation of human plasmacytoid dendritic cells. Eur J Immunol 2005 35 : 2184 2190.
40. Wang H, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999 285 : 248 251.
41. Rovere-Querini P, et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 2004 5 : 825 830.
42. Shiratsuchi A, Watanabe I, Takeuchi O, Akira S, Nakanishi Y. Inhibitory effect of Toll-like receptor 4 on fusion between phagosomes and endosomes/lysosomes in macrophages. J Immunol 2004 172 : 2039 2047.
43. Delamarre L, Couture R, Mellman I, Trombetta ES. Enhancing immunogenicity by limiting susceptibility to lysosomal proteolysis. J Exp Med 2006 203 : 2049 2055.
44. Porgador A, Yewdell JW, Deng Y, Bennink JR, Germain RN. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 1997 6 : 715 726.
45. Arbour NC, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000 25 : 187 191.
46. Rallabhandi P, et al. Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure, and signaling. J Immunol 2006 177 : 322 332.
47. Agnese DM, et al. Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 2002 186 : 1522 1525.
48. Schroder NW, Schumann RR. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis 2005 5 : 156 164.
49. Lorenz E, Mira JP, Frees KL, Schwartz DA. Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 2002 162 : 1028 1032.
50. Cheng I, Plummer SJ, Casey G, Witte JS. Toll-like receptor 4 genetic variation and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2007 16 : 352 355.
51. Burnet M. Cancer; a biological approach. I. The processes of control. Br Med J 1957 1 : 779 786.
52. Shankaran V, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001 410 : 1107 1111.
53. Borg C, et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 2004 114 : 379 388.
54. Crowe NY, Smyth MJ, Godfrey DI. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med 2002 196 : 119 127.
55. Taieb J, et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 12 : 214 219.
56. Ullrich E, et al. Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells. Cancer Res 2007 67 : 851 853.
57. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006 6 : 715 727.
58. Galluzzi L, et al. Cell death modalities: classification and pathophysiological implications. Cell Death Differ 2007 14 : 1237 1243.
59. Zitvogel L, Casares N, Pequignot MO, Chaput N, Albert ML, Kroemer G. Immune response against dying tumor cells. Adv Immunol 2004 84 : 131 179.
60. Ghiringhelli F, Apetoh L, Housseau F, Kroemer G, Zitvogel L. Links between innate and cognate tumor immunity. Curr Opin Immunol 2007 19 : 224 231.
61. Obeid M, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007 13 : 54 61.
62. Obeid M, et al. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ 2007 Jul 27.
63. Obeid M, et al. Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from 'silent' to immunogenic. Cancer Res 2007 67 : 7941 7944.
64. Messmer D, et al. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol 2004 173 : 307 313.
65. Blander JM, Medzhitov R. On regulation of phagosome maturation and antigen presentation. Nat Immunol 2006 7 : 1029 1035.
66. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004 303 : 1529 1531.
67. Heil F, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004 303 : 1526 1529.
68. Hemmi H, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000 408 : 740 745.
69. Tian J, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007 8 : 487 496.
70. Ivanov S, et al. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 2007 110 : 1970 1981.
71. Marshak-Rothstein A, Rifkin IR. Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease. Annu Rev Immunol 2007 25 : 419 441.
72. Lake RA, Robinson BW. Immunotherapy and chemotherapy - a practical partnership. Nat Rev Cancer 2005 5 : 397 405.
73. Baguley BC. Antivascular therapy of cancer: DMXAA. Lancet Oncol 2003 4 : 141 148.
74. Jassar AS, et al. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. Cancer Res 2005 65 : 11752 11761.
75. Roberts ZJ, et al. The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis. J Exp Med 2007 204 : 1559 1569.
76. Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S, Dhodapkar MV. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 2007 109 : 4839 4845.
77. Frenzel H, Hoffmann B, Brocks C, Schlenke P, Pries R, Wollenberg B. Toll-like receptor interference in myeloid dendritic cells through head and neck cancer. Anticancer Res 2006 26 : 4409 4413.
78. Genne P, Duchamp O, Solary E, Magnette J, Belon JP, Chauffert B. Cinchonine per os: efficient circumvention of P-glycoprotein-mediated multidrug resistance. Anticancer Drug Des 1995 10 : 103 118.
79. Wattel E, et al. Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study. Br J Haematol 1998 102 : 1015 1024.
80. Van Rijn BB, Roest M, Franx A, Bruinse HW, Voorbij HA. Single step high-throughput determination of Toll-like receptor 4 polymorphisms. J Immunol Methods 2004 289 : 81 87.